Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Fig. 1 | Respiratory Research

Fig. 1

From: A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial

Fig. 1

Trial Flow: 23 out of 130 screened patients (screening failure rate 82%) were randomized in a 1:1 ratio to receive SB010 (10 mg bid) or matching placebo. The dropout rate was 3/12 in the SB010 arm and 1/11 in the placebo arm. Reasons for dropout in the SB010 arm were not related to the study drug in 2 cases and may have been study drug-related in one case (mild AE in conjunction with patient’s wish). ITT: Intention-to-treat population; PP: Per-Protocol population. *Numbers for single screening failure reasons do not add up to total number, because two or more reasons could co-exist in one patient

Back to article page